Why the study?
Does elevated plasma procalcitonin predict major adverse cardiac events and left ventricular remodeling in patients with acute myocardial infarction?
Does elevated plasma procalcitonin predict major adverse cardiac events and left ventricular remodeling in patients with acute myocardial infarction?
Elevated procalcitonin levels post-AMI serve as a prognostic marker for increased risk of MACE and adverse left ventricular remodeling.
May support post-AMI risk stratification; hypothesis-generating and should not yet change practice.
BACKGROUND: Procalcitonin is involved in the inflammatory response and is associated with adverse prognosis in certain conditions. AIMS: To investigate the association between procalcitonin and major adverse cardiac events (MACE), left ventricular (LV) function and remodelling following acute myocardial infarction (AMI). METHODS: Plasma procalcitonin was measured in 977 patients with AMI. Subjects were followed for MACE (median 671 days). A subgroup underwent echocardiography at discharge and follow-up LV function and volume assessment. RESULTS: Procalcitonin was associated with MACE on uni- and multivariable analysis. Kaplan-Meier assessment revealed an adverse outcome in subjects with procalcitonin above the median. Procalcitonin was related to markers of LV dysfunction and remodelling. CONCLUSION: Procalcitonin is associated with MACE, LV dysfunction and remodelling post-AMI.
No takes yet. Share an insight, caveat, or question.
Kelly et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: